June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Ocular Toxicity Profile of Novel PI3K/MEK Dual Inhibitor
Author Affiliations & Notes
  • Andrew Smith
    Ophthalmology and Visual Sciences, University of Michigan, Fairport, New York, United States
  • Mercy D Pawar
    Ophthalmology and Visual Sciences, University of Michigan, Fairport, New York, United States
  • Cagri G Besirli
    Ophthalmology and Visual Sciences, University of Michigan, Fairport, New York, United States
  • Marcian E Van Dort
    Center for Molecular Imaging, University of Michigan, Ann Arbor, Michigan, United States
  • Brian D Ross
    Center for Molecular Imaging, University of Michigan, Ann Arbor, Michigan, United States
    Department of Radiology, University of Michigan, Ann Arbor, Michigan, United States
  • Stefanie Galbán
    Center for Molecular Imaging, University of Michigan, Ann Arbor, Michigan, United States
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States
  • Footnotes
    Commercial Relationships   Andrew Smith, None; Mercy Pawar, None; Cagri Besirli, None; Marcian Van Dort, None; Brian Ross, None; Stefanie Galbán, None
  • Footnotes
    Support  MCubed, University of Michigan, grant U049581
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 251. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Andrew Smith, Mercy D Pawar, Cagri G Besirli, Marcian E Van Dort, Brian D Ross, Stefanie Galbán; Ocular Toxicity Profile of Novel PI3K/MEK Dual Inhibitor. Invest. Ophthalmol. Vis. Sci. 2017;58(8):251.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the ocular toxicity of a novel dual kinase inhibitor targeting MEK and PI3K pathways using in vitro and in vivo analysis.

Methods : 661W, in vitro photoreceptor cell line model and ARPE-19, adult retinal pigment epithelium cells were treated with PI3K inhibitor (ZSTK474), MEK inhibitor (PD0325901), ZSTK474 & PD0325901 combined and dual inhibitor compounds targeting both the PI3K/Akt/mTOR and Ras/ MEK/ERK pathways. Cells were incubated at concentrations 1uM, 5uM, 10uM, 25uM, 50uM and 100uM for 4hours and 24hours and western blots performed to determine PI3K and MEK activity. Cell Viability and caspase activity were measured using luminescent cleavage assay kit after 24hrs of incubation with the inhibitors. Intraocular injections were performed in an animal model to determine in vivo toxicity profile.

Results : For both cell lines. a dose-dependent decrease in levels of p-AKT and p-ERK1/2 was observed for the dual inhibitors. The PI3K inhibitor (ZSTK474) and MEK inhibitor (PD0325901) only inhibited Akt phosphorylation or Erk phosphorylation, respectively. The combined treatment of PI3K inhibitor (ZSTK474) and MEK inhibitor (PD0325901) showed complete inhibition of both Akt and Erk phosphorylation. Inhibition of the PI3K pathway with ZSTK474 in 661W cells led to increased caspase activity and cell death, which was potentiated by MEK inhibitor PD0325901. Dual inhibitor was less toxic to 661W cells, causing less caspase activity and loss of cell viability. In contrast to 661W cells, ARPE-19 cells were more vulnerable to MEK inhibition and resisted the toxic effects of dual inhibitor compared to individual or combination of PI3K and MEK inhibitors. MEK inhibitor led to retinal necrosis and retinal hemorrhages in vivo, which was observed with less intensity using the dual inhibitor.

Conclusions : A novel dual inhibitor of PI3K and MEK inhibited Akt and ERK phosphorylation in 661W and ARPE cells. The dual inhibitor demonstrated better toxicity profile compared to the combination of agents targeting each pathway independently. By blocking the key intracellular pathways that regulate cell survival and proliferation, PI3K/MEK dual inhibitor compounds could be potential therapeutic agents for malignant tumors with improved ocular and neurotoxic profiles.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×